WARNING: "Solid Contributors"....Don't shoot the messenger. Only passing on information that may, or may not, reflect the posters personal opinions. Thank You!!
Hold rating...Price Target $8.50....The chance for a strategic deal are low over i the near term as Vascepa faces risks of a tepid debut..
Just look up this firm. They are major league shady. Just another hired gun for the shorts. For now, the shorts are running the show. Just keep loading up at these gift prices. It should all start turning around in the April / May time frame.
Sentiment: Strong Buy
I think any future cash flow analysis at this juncture in the sales life of Vascepa is totally worthless, period.
There is NO way you can extrapolate future cash flow discounted to present value based on three months of sales trends starting at day one,
Gosh...So based on thumbs down ratio on this post, do most of you solid contributors here then think there is a good chance for a strategic buyout at a premium to current levels, and generic competition and a slow launch of Vascepa should not keep the stock under "negative pressure"? TIA for the your solid thoughts on these issues!
Understand. I do the same thing. I first look to see what JL is advising people to buy at the time, then talk to the institutional global market traders at GS. Ironically, they always seem to agree with JL!
More from "Briefings",,,,Neutral Chardan Capital Markets comments re AMRN...
,,,"Although an acquisition of Amarin could reward investors with a premium above the current share price, firm remains on the sidelines as we believe the chance of a near term strategic deal is low. Firm believes AMRN stock will remain under negative pressure, based on the risk of a slow launch and potential generic cometition....."